Read about chromosomal instability in the March issue

Latest Reviews

  • Opinion |

    The aberrant tumour vasculature and the associated angiogenic factors have been implicated in tumour immune evasion and progression. Herein, the authors provide their perspectives on how normalization of the tumour microenvironment using antiangiogenic agents could potentially increase the effectiveness of immunotherapies and improve the outcomes of patients with cancer. The authors also highlight important considerations for future research in this area.

    • Dai Fukumura
    • , Jonas Kloepper
    • , Zohreh Amoozgar
    • , Dan G. Duda
    •  & Rakesh K. Jain
  • Review |

    The PI3K–AKT–mTOR pathway has key roles in tumorigenesis and is dysregulated in most cancers. Consequently, numerous drugs that target key nodes of this pathway have been developed, although few of these agents have been approved for the treatment of cancer. Herein, the authors review the current experience with anticancer therapies that target the PI3K–AKT–mTOR pathway, discuss the challenges that have limited the clinical translation of these agents, and provide perspectives for the future development of these drugs.

    • Filip Janku
    • , Timothy A. Yap
    •  & Funda Meric-Bernstam
  • Review |

    The development of cancer involves several epigenomic alterations, and the presence of certain alterations before the development of cancer is associated with cancer risk. In this Review, the authors describe the potential of epigenomics-based assays to predict an individual's risk of cancer, including discussions of technical, practical and societal issues regarding the implementation of such assays.

    • Martin Widschwendter
    • , Allison Jones
    • , Iona Evans
    • , Daniel Reisel
    • , Joakim Dillner
    • , Karin Sundström
    • , Ewout W. Steyerberg
    • , Yvonne Vergouwe
    • , Odette Wegwarth
    • , Felix G. Rebitschek
    • , Uwe Siebert
    • , Gaby Sroczynski
    • , Inez D. de Beaufort
    • , Ineke Bolt
    • , David Cibula
    • , Michal Zikan
    • , Line Bjørge
    • , Nicoletta Colombo
    • , Nadia Harbeck
    • , Frank Dudbridge
    • , Anne-Marie Tasse
    • , Bartha M. Knoppers
    • , Yann Joly
    • , Andrew E. Teschendorff
    • , Nora Pashayan
    •  & on behalf of the FORECEE (4C) Consortium
  • Review |

    The combination of immunotherapies with other therapeutic modalities, including anti-angiogenic agents, is currently under investigation to improve the outcomes of patients receiving immunotherapies. In this article, the authors review the effects mediated by anti-angiogenic agents that might increase the efficacy of immunotherapies and discuss the possibility that immunotherapies might increase the efficacy of anti-angiogenic agents and/or promote changes in the tumour vasculature.

    • Kabir A. Khan
    •  & Robert S. Kerbel
  • Review |

    The interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In this Review, the authors describe the clinical potential of agents designed to inhibit the IL-6/JAK/STAT3 signalling pathway, either alone or in combination with other agents, in patients with cancer.

    • Daniel E. Johnson
    • , Rachel A. O'Keefe
    •  & Jennifer R. Grandis
  • Review |

    The safety of elective exogenous hormonal exposure among breast cancer survivors or women at high risk of having the disease has been debated for decades. Herein, the authors discuss the available data and present clinical recommendations regarding four areas of potential exogenous exposure to hormones: hormonal contraception; systemic hormone-replacement therapy; localized hormone-replacement therapy; and hormonal manipulation for fertility preservation or enhancement. Further research is needed to improve patient management in the future.

    • Ines Vaz-Luis
    •  & Ann H. Partridge

News & Comment

Natureevents Directory